The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

DSpace/Manakin Repository

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

Citable link to this page

 

 
Title: The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
Author: Mishima, Yuji; Paiva, Bruno; Shi, Jiantao; Park, Jihye; Manier, Salomon; Takagi, Satoshi; Massoud, Mira; Perilla-Glen, Adriana; Aljawai, Yosra; Huynh, Daisy; Roccaro, Aldo M.; Sacco, Antonio; Capelletti, Marzia; Detappe, Alexandre; Alignani, Diego; Anderson, Kenneth C.; Munshi, Nikhil C.; Prosper, Felipe; Lohr, Jens G.; Ha, Gavin; Freeman, Samuel S.; Van Allen, Eliezer M.; Adalsteinsson, Viktor A.; Michor, Franziska; San Miguel, Jesus F.; Ghobrial, Irene M.

Note: Order does not necessarily reflect citation order of authors.

Citation: Mishima, Y., B. Paiva, J. Shi, J. Park, S. Manier, S. Takagi, M. Massoud, et al. 2017. “The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.” Cell reports 19 (1): 218-224. doi:10.1016/j.celrep.2017.03.025. http://dx.doi.org/10.1016/j.celrep.2017.03.025.
Full Text & Related Files:
Abstract: Summary The development of sensitive and non-invasive “liquid biopsies” presents new opportunities for longitudinal monitoring of tumor dissemination and clonal evolution. The number of circulating tumor cells (CTCs) is prognostic in multiple myeloma (MM), but there is little information on their genetic features. Here, we have analyzed the genomic landscape of CTCs from 29 MM patients, including eight cases with matched/paired bone marrow (BM) tumor cells. Our results show that 100% of clonal mutations in patient BM were detected in CTCs and that 99% of clonal mutations in CTCs were present in BM MM. These include typical driver mutations in MM such as in KRAS, NRAS, or BRAF. These data suggest that BM and CTC samples have similar clonal structures, as discordances between the two were restricted to subclonal mutations. Accordingly, our results pave the way for potentially less invasive mutation screening of MM patients through characterization of CTCs.
Published Version: doi:10.1016/j.celrep.2017.03.025
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439509/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33029966
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters